Business Context and Reporting Period
Company: Cyclacel Pharmaceuticals, Inc. (Note: Input metadata referenced "Bio Green Med Solution, Inc.", but the filing text identifies the registrant as Cyclacel Pharmaceuticals, Inc.)
Filing Type: Form 8-K (Current Report)
Date of Report: November 14, 2023
Subject: Non-reliance on previously issued financial statements and announcement of a restatement due to material unintentional errors in accounting for contract research service deposits.
Key Financial Metrics and Impact
The filing details a restatement affecting historical financial results from 2021 through Q2 2023. The primary error involved the incorrect expensing of vendor invoices totaling approximately $0.5 million that should have been capitalized as non-current deposits.
- 2021 Net Loss Adjustment: Expected decrease of $0.5 million from the previously reported net loss of $18.9 million.
- Asset Adjustments: Expected increase in total assets of $0.5 million for the following periods:
- 2021: Previously reported $42.6 million
- 2022: Previously reported $27.5 million
- Q1 2023: Previously reported $22.1 million
- Q2 2023: Previously reported $16.4 million
- Cash Flow: Cash and cash equivalents are not impacted by the restatement.
- Specific Period Impacts:
- Q3 2021: Overstatement of operating loss by $293,845.
- Q4 2021: Overstatement of operating loss by $255,450.
Material Changes and Causes
The material changes stem from an error identified during contract renegotiations for the 065-102 study and the return of a $1.1 million contract deposit. The error occurred between September and November 2021:
- Root Cause: Vendor invoices totaling $549,295 related to clinical trial activity were correctly expensed initially. However, subsequent duplicate invoices received in September and November 2021 were incorrectly expensed again instead of being capitalized as non-current deposits.
- Result: This led to an overstatement of operating losses and an understatement of non-current deposits in the affected periods.
Guidance, Outlook, and Risks
Management Commentary and Controls:
- Management concluded that disclosure controls and procedures were not effective as of December 31, 2021, due to a material weakness in internal control over financial reporting regarding the accounting treatment of deposit-related invoices.
- The Audit Committee and management have discussed these matters with the independent registered public accounting firm, RSM US LLP.
- The Company plans to file an amendment to the 2022 Annual Report (Form 10-K) to include restated financial statements for 2021 and 2022.
- Amendments to Quarterly Reports (Form 10-Q) for Q3 2021 and all 2022 quarters are expected.
- The Q3 2023 Form 10-Q will include recast financial statements for Q1 and Q2 2023.
- The Company cannot provide assurance that the restatement amounts will not change materially as the process is finalized.
- Investors are advised not to rely on previously issued earnings releases or investor presentations describing the affected financials.
Investor Verification Checklist
- Verify the final restated net loss and total asset figures once the amended 2022 Annual Report is filed.
- Review the upcoming Q3 2023 Form 10-Q for recast Q1 and Q2 2023 financial data.
- Monitor the Company's disclosure regarding the remediation plan for the identified material weakness in internal controls.
- Confirm that cash and cash equivalents remain unchanged as stated in the filing.
- Check for any updates on the 065-102 study contract renegotiations and the status of the $1.1 million deposit return.